Skip to main content
. 2021 Mar 16;12:642131. doi: 10.3389/fendo.2021.642131

Table 1.

Prevalence of complications and their distribution in genders.

Complication Number of patients % F/M %F %M
Lipid disorders 133 74 90/43 76 72
Hypertension 103 58 72/31 61 52
Goiter 93 52 65/28 55 47
Joint degeneration 72 40 46/26 39 43
Hypopituitarism 66 37 36/30 30 50
 Secondary hypogonadism 33 18 13/20 11 33
 Secondary adrenal insufficiency 46 26 25/21 21 35
 Secondary hypothyroidism 40 22 21/19 18 32
 Panhypopituitarism 18 10 6/12 5 20
Changes in echocardiograms* 61 34 36/25 30 42
Prediabetes** 61 34 33/28 28 47
Diabetes*** 59 33 44/15 37 25
Cholelithiasis 51 28 36/15 30 25
Arrhythmias 35 20 20/15 17 25
Osteoporosis 22 12 15/7 13 12
Nephrolithiasis 22 12 13/9 11 15
Colonic polyps 21 12 13/8 11 13
Ischemic heart disease 12 7 11/1 9 2
Heart failure 11 6 6/5 5 8
Carpal tunnel syndrome 8 4 7/1 6 2
Sleep apnea 3 2 1/2 1 3

*Left ventricular and interventricular septum hypertrophy, diastolic dysfunction, valvular defects – mainly mitral valve regurgitation, improper atrial and ventricular dimensions.

**Diagnostic criteria were: fasting plasma glucose between 100 and 125 mg/dL or two-hour plasma glucose value between 140 and 199 mg/dL.

***Diagnostic criteria were: fasting plasma glucose ≥126 mg/dL repeated twice or two-hour plasma glucose value of ≥200 mg/dL during a 75-g oral glucose test (OGTT), or symptomatic hyperglycemia (weight loss, polyuria, polydipsia) and blood glucose ≥200 mg/dL.